TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$18.6b

TTY Biopharm Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure4.2yrs
Board average tenure8.6yrs

Recent management updates

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25
Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07
TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19
TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10
What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25
How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

CEO

TTY Biopharm has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Kuo-Chiang Chang
Chief Financial Officerless than a yearno datano data
Shu-Wen Wang
Accounting Officer9.4yrsno datano data
Shu-Fen Huang
Chief Legal & Compliance Officer2.8yrsno datano data
Wei-Ying Yin
Director of Public Affairs Departmentno datano datano data
Jen-Yang Chang
Chief Human Resource Officer5.7yrsno datano data
Si-Yuan Yang
Senior Vice President15.7yrsno datano data
Allen Chu
Head of Intensive Care Business Unitno datano datano data
Ching-Lan Hou
General Manager2.8yrsno datano data
Yung-Min Chiang
Chief Auditorno datano datano data

4.2yrs

Average Tenure

Experienced Management: 4105's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Tze-Kaing Yang
Director8.6yrsno datano data
Chuan-Quan Lin
Chairman of the Board13.6yrsno data0.084%
NT$ 15.8m
Ming-Ling Hsueh
Independent Director8.6yrsno datano data
Wen-Hwa Chang
Vice Chairman29.5yrsno data7.56%
NT$ 1.4b
Ying-Ying Liao
Director8.6yrsno datano data
Carl Hsiao
Representative Director5.8yrsno data0.35%
NT$ 66.1m
Ming-Dao Chang
Independent Directorless than a yearno datano data
An-Li Zheng
Independent Directorless than a yearno datano data
Shi-Chang Xu
Representative Directorless than a yearno datano data

8.6yrs

Average Tenure

69yo

Average Age

Experienced Board: 4105's board of directors are considered experienced (8.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 08:00
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TTY Biopharm Company Limited is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jerry SuCredit Suisse
Christine WangDaiwa Securities Co. Ltd.
Jiahong LiuE.Sun Securities Investment Consulting Co. Ltd.